BioSpace News Archive

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the BofA Securities Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Seattle Genetics Seattle Genetics, Inc.

Bayer to cover testing costs for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) The results of a genomic cancer test can help healthcare providers determine appropriate treatment plans for people with an NTRK gene fusion NTRK gene fusions can drive tumor growth and are more common in MSI-H mCRC and RAI-R DTC cases than other subt

Grant Application Submitted to California Institute for Regenerative Medicine for Additional Funding

Investment banking leaders known for pushing the boundaries of technology and innovation to lend their unique perspectives to the leader in tech-enabled drug discovery.

Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the appointment of five new members to its Board of Directors from HLB, Co. Ltd (“HLB”) and its HLB Bio subsidiaries. “I am delighted to welcome

Sharps Compliance Corp. announced that David P. Tusa, Chief Executive Officer has been invited to participate in Oppenheimer’s 5th Annual Emerging Growth Conference, which will take place virtually on Tuesday, May 12, 2020.

VolitionRx Limited announced it will host a conference call on Friday, May 8, at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter 2020, in addition to providing a business update.

Enables a Single Audit at Each Site to Satisfy Quality Requirements Across Australia, Brazil, Canada, Japan and the U.S; Reduces Regulatory Risk During the Manufacturing of Medical Devices

Invectys SA, a clinical-stage immuno-oncology company developing novel therapies for the treatment of advanced cancers, announced the appointment of Dennis J. Purcell, life sciences industry veteran and founder of Aisling Capital LLC, as Strategic Advisor to Invectys Therapeutics.

Castellum, Inc. (OTC: ONOV) is pleased to announce record quarterly revenue and EBITDA for the first quarter ended March 31, 2020. The Company expects to file its 2020 Q1 report www.otcmarkets.com within the next 30 days, well ahead of the July deadline. Castellum’s financial picture continues to brighten. Revenue for Q1 2020 was a record $3.4 million. EBITDA, a non-GAAP measure, was approximately $372,000. Cash on hand at quarter end was ov